tetano
Editor, Senior Moderator
Expert Rev Anti Infect Ther
. 2021 Mar 14.
doi: 10.1080/14787210.2021.1902805. Online ahead of print.
Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials
Nida Bokharee[SUP] 1 [/SUP], Yusra Habib Khan[SUP] 2 [/SUP], Aisha Khokhar[SUP] 1 [/SUP], Tauqeer Hussain Mallhi[SUP] 2 [/SUP], Nasser Hadal Alotaibi[SUP] 2 [/SUP], Maria Rasheed[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: Currently there is no approved therapeutic entity for coronavirus disease 2019 (COVID-19) and clinicians are primarily relying on drug repurposing. However, findings across studies are widely disparate, making it difficult to draw firm conclusions. Since clinicians need accurate evidence to treat COVID-19, this manuscript systematically analyzed the published and ongoing studies evaluating the pharmacological interventions for COVID-19.
Areas covered: A systematic search of observational studies and Clinical Trials on the treatment and prevention of COVID-19 was performed by using various databases from inception to December 02, 2020.
Expert opinion: A total of 460 studies met the inclusion criteria. Of these, 37 were research studies, 386 were ongoing trials and 37 were completed trials. Anti-virals, steroids, anti-malarial, plasma exchange and monoclonal antibodies were the most common treatment modalities used alone or in combination in these studies. However, tocilizumab, plasma exchange and steroids have shown significant improvements in patient's clinical and radiological status. Tocilizumab reported minimum hospital stay of 2 days along with maximum recovery and patient`s stability rate. Existing literature demonstrate promising results of tocilizumab, plasma exchange and steroids among COVID-19 patients. Nevertheless, these studies are accompanied by several methodological disparities which should be considered while interpreting the results.
Keywords: COVID-19; Chloroquine; Coronavirus; Hydroxychloroquine; Pharmacological Intervention; Prevention; Remdesivir; SARS-CoV-2; Treatment.
. 2021 Mar 14.
doi: 10.1080/14787210.2021.1902805. Online ahead of print.
Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials
Nida Bokharee[SUP] 1 [/SUP], Yusra Habib Khan[SUP] 2 [/SUP], Aisha Khokhar[SUP] 1 [/SUP], Tauqeer Hussain Mallhi[SUP] 2 [/SUP], Nasser Hadal Alotaibi[SUP] 2 [/SUP], Maria Rasheed[SUP] 1 [/SUP]
Affiliations
- PMID: 33719819
- DOI: 10.1080/14787210.2021.1902805
Abstract
Introduction: Currently there is no approved therapeutic entity for coronavirus disease 2019 (COVID-19) and clinicians are primarily relying on drug repurposing. However, findings across studies are widely disparate, making it difficult to draw firm conclusions. Since clinicians need accurate evidence to treat COVID-19, this manuscript systematically analyzed the published and ongoing studies evaluating the pharmacological interventions for COVID-19.
Areas covered: A systematic search of observational studies and Clinical Trials on the treatment and prevention of COVID-19 was performed by using various databases from inception to December 02, 2020.
Expert opinion: A total of 460 studies met the inclusion criteria. Of these, 37 were research studies, 386 were ongoing trials and 37 were completed trials. Anti-virals, steroids, anti-malarial, plasma exchange and monoclonal antibodies were the most common treatment modalities used alone or in combination in these studies. However, tocilizumab, plasma exchange and steroids have shown significant improvements in patient's clinical and radiological status. Tocilizumab reported minimum hospital stay of 2 days along with maximum recovery and patient`s stability rate. Existing literature demonstrate promising results of tocilizumab, plasma exchange and steroids among COVID-19 patients. Nevertheless, these studies are accompanied by several methodological disparities which should be considered while interpreting the results.
Keywords: COVID-19; Chloroquine; Coronavirus; Hydroxychloroquine; Pharmacological Intervention; Prevention; Remdesivir; SARS-CoV-2; Treatment.